Spruce Biosciences (SPRB) Projected to Post Earnings on Wednesday

Spruce Biosciences (NASDAQ:SPRB) is projected to issue its quarterly earnings data before the market opens on Wednesday, March 12th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $0.89 million for the quarter.

Spruce Biosciences Stock Down 1.7 %

SPRB opened at $0.35 on Monday. The company has a quick ratio of 5.36, a current ratio of 5.36 and a debt-to-equity ratio of 0.01. The stock has a market cap of $14.59 million, a price-to-earnings ratio of -0.38 and a beta of 2.34. Spruce Biosciences has a twelve month low of $0.34 and a twelve month high of $5.53. The company’s 50-day moving average price is $0.39 and its two-hundred day moving average price is $0.45.

Analyst Upgrades and Downgrades

A number of analysts recently commented on SPRB shares. Guggenheim restated a “neutral” rating on shares of Spruce Biosciences in a research note on Thursday, December 12th. HC Wainwright restated a “neutral” rating on shares of Spruce Biosciences in a research note on Monday, December 16th. Royal Bank of Canada restated a “sector perform” rating and set a $1.50 price target (down from $2.00) on shares of Spruce Biosciences in a research note on Wednesday, December 11th. Citizens Jmp cut shares of Spruce Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Oppenheimer reiterated a “market perform” rating on shares of Spruce Biosciences in a research note on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating, According to data from MarketBeat, Spruce Biosciences presently has an average rating of “Hold” and a consensus price target of $2.38.

About Spruce Biosciences

Spruce Biosciences, Inc, a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial.